Index -
P/E 6.95
EPS (ttm) 0.17
Insider Own 1.69%
Shs Outstand 78.23M
Perf Week 11.32%
Market Cap 92.35M
Forward P/E -
EPS next Y -0.43
Insider Trans -2.10%
Shs Float 76.93M
Perf Month 18.00%
Income 13.83M
PEG -
EPS next Q -0.20
Inst Own 65.49%
Short Float 5.77%
Perf Quarter -5.60%
Sales 126.62M
P/S 0.73
EPS this Y -328.04%
Inst Trans 1.30%
Short Ratio 4.05
Perf Half Y -28.05%
Book/sh -0.30
P/B -
EPS next Y -908.36%
ROA 7.68%
Short Interest 4.44M
Perf Year -18.90%
Cash/sh 1.50
P/C 0.79
EPS next 5Y -0.90%
ROE -
52W Range 0.83 - 5.85
Perf YTD -23.87%
Dividend Est. -
P/FCF -
EPS past 5Y 67.21%
ROI -
52W High -79.83%
Beta 1.03
Dividend TTM -
Quick Ratio 1.04
Sales past 5Y 28.25%
Gross Margin 98.55%
52W Low 41.66%
ATR (14) 0.10
Dividend Ex-Date -
Current Ratio 1.04
EPS Y/Y TTM 205.69%
Oper. Margin 5.30%
RSI (14) 60.04
Volatility 12.73% 9.35%
Employees 122
Debt/Eq -
Sales Y/Y TTM 33.66%
Profit Margin 10.92%
Recom 2.00
Target Price 5.29
Option/Short Yes / Yes
LT Debt/Eq -
EPS Q/Q 82.38%
Payout -
Rel Volume 0.84
Prev Close 1.16
Sales Surprise 95.51%
EPS Surprise 140.63%
Sales Q/Q 26.71%
Earnings Nov 07 AMC
Avg Volume 1.10M
Price 1.18
SMA20 15.22%
SMA50 10.48%
SMA200 -24.91%
Trades
Volume 920,812
Change 1.72%
Date
Action
Analyst
Rating Change
Price Target Change
May-28-24 Upgrade
Piper Sandler
Neutral → Overweight
$2.25 → $3.50
May-09-24 Upgrade
Wedbush
Neutral → Outperform
$8
May-06-24 Upgrade
Jefferies
Hold → Buy
$2.50 → $8
Apr-22-24 Upgrade
JP Morgan
Underweight → Neutral
Nov-14-22 Downgrade
BMO Capital Markets
Outperform → Market Perform
$3 → $2.60
Jul-07-22 Downgrade
Wedbush
Outperform → Neutral
$6 → $2
Jul-07-22 Downgrade
Piper Sandler
Overweight → Neutral
$10 → $1.50
Jul-07-22 Downgrade
Mizuho
Buy → Neutral
$16 → $4
Jul-07-22 Downgrade
Jefferies
Buy → Hold
$12 → $2
Jun-24-22 Initiated
BMO Capital Markets
Outperform
$9
Jan-18-22 Upgrade
Barclays
Underweight → Overweight
$7
Nov-15-21 Initiated
BTIG Research
Buy
$16
May-28-21 Downgrade
Barclays
Equal Weight → Underweight
$9 → $7
Mar-29-21 Initiated
JP Morgan
Overweight
$14
Mar-23-21 Upgrade
Jefferies
Hold → Buy
Sep-22-20 Downgrade
Guggenheim
Buy → Neutral
Jun-01-20 Downgrade
Jefferies
Buy → Hold
$16 → $10
May-14-20 Reiterated
H.C. Wainwright
Buy
$16 → $12
Mar-24-20 Upgrade
Wedbush
Neutral → Outperform
Mar-04-20 Initiated
Barclays
Equal Weight
$7
Show Previous Ratings
Nov-27-24 08:00AM
Nov-19-24 09:35AM
Nov-08-24 11:54AM
(Thomson Reuters StreetEvents) +9.00%
02:32AM
Nov-07-24 05:55PM
04:49PM
Loading…
04:49PM
(Associated Press Finance)
04:10PM
Nov-06-24 07:52AM
Oct-31-24 08:00AM
Sep-09-24 08:00AM
Sep-04-24 08:00AM
Aug-10-24 08:18AM
Aug-08-24 09:56PM
05:46PM
(Associated Press Finance)
04:10PM
08:00AM
Loading…
Aug-01-24 08:00AM
Jul-25-24 02:26AM
Jun-18-24 08:00AM
Jun-17-24 04:15PM
Jun-05-24 06:00AM
Jun-03-24 09:17AM
May-29-24 06:25AM
May-22-24 04:05PM
May-16-24 04:15PM
May-15-24 11:14AM
May-09-24 04:17PM
11:56AM
11:32AM
08:12AM
(Thomson Reuters StreetEvents)
07:48AM
07:29AM
Loading…
07:29AM
04:01AM
May-08-24 09:58PM
04:30PM
(Associated Press Finance)
04:10PM
04:10PM
May-07-24 04:15PM
May-06-24 07:09AM
May-02-24 08:08AM
07:37AM
May-01-24 12:11PM
11:43AM
08:00AM
Apr-08-24 08:00AM
Apr-03-24 08:00AM
Mar-21-24 08:00AM
Mar-18-24 08:00AM
Mar-12-24 09:12AM
08:30AM
06:46AM
(Thomson Reuters StreetEvents)
Mar-11-24 05:34PM
05:20PM
04:10PM
Mar-04-24 08:00AM
Feb-27-24 11:52AM
08:00AM
Jan-24-24 08:00AM
Jan-12-24 08:00AM
Jan-04-24 08:00AM
Dec-21-23 08:00AM
Nov-13-23 12:00PM
Nov-08-23 10:15AM
Nov-07-23 05:05PM
(Associated Press Finance)
04:15PM
Nov-01-23 08:00AM
Oct-31-23 08:00AM
Oct-30-23 08:00AM
Oct-18-23 04:30PM
Sep-05-23 04:05PM
Aug-25-23 09:35AM
Aug-10-23 04:05PM
Aug-08-23 05:30PM
04:26PM
(Associated Press Finance)
04:15PM
Aug-01-23 08:00AM
Jul-20-23 09:00AM
Jul-17-23 08:00AM
Jun-30-23 08:00AM
Jun-08-23 09:02AM
Jun-01-23 04:05PM
May-11-23 06:05AM
May-10-23 08:13AM
(Thomson Reuters StreetEvents) +5.81%
May-09-23 05:35PM
04:26PM
04:15PM
May-05-23 06:34AM
May-01-23 04:01PM
10:01AM
Apr-27-23 10:03AM
Apr-25-23 04:05PM
Mar-30-23 11:26AM
Mar-29-23 06:06AM
Mar-28-23 01:35PM
Mar-27-23 05:35PM
04:15PM
Mar-22-23 07:23PM
Mar-20-23 06:14AM
Feb-28-23 04:05PM
Feb-07-23 06:07AM
Jan-26-23 07:00AM
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Landau Jeffrey B Chief Business Officer Aug 20 '24 Option Exercise 0.00 11,250 0 123,237 Aug 22 06:01 PM Landau Jeffrey B Chief Business Officer Aug 20 '24 Sale 1.23 4,181 5,139 119,056 Aug 22 06:01 PM BELVIN MARCIA SVP, Chief Scientific Officer Aug 20 '24 Option Exercise 0.00 11,250 0 179,829 Aug 22 06:01 PM BELVIN MARCIA SVP, Chief Scientific Officer Aug 20 '24 Sale 1.23 4,181 5,139 175,648 Aug 22 06:01 PM ROWLAND LLOYD A General Counsel Aug 20 '24 Option Exercise 0.00 11,250 0 134,978 Aug 22 06:00 PM ROWLAND LLOYD A General Counsel Aug 20 '24 Sale 1.23 4,181 5,139 130,797 Aug 22 06:00 PM Ogden Christopher Chief Financial Officer Aug 20 '24 Option Exercise 0.00 6,875 0 110,061 Aug 22 05:59 PM Ogden Christopher Chief Financial Officer Aug 20 '24 Sale 1.23 1,984 2,439 108,077 Aug 22 05:59 PM McCarthy Sean A. CEO Aug 20 '24 Option Exercise 0.00 37,500 0 671,749 Aug 22 05:58 PM McCarthy Sean A. CEO Aug 20 '24 Sale 1.23 13,898 17,082 657,851 Aug 22 05:58 PM McCarthy Sean A. CEO Mar 26 '24 Option Exercise 1.57 109,768 172,874 634,249 Mar 28 07:12 PM ROWLAND LLOYD A General Counsel Mar 19 '24 Sale 2.09 5,268 10,986 117,728 Mar 21 04:41 PM McCarthy Sean A. CEO Mar 19 '24 Sale 2.09 20,223 42,175 524,481 Mar 21 04:40 PM Ogden Christopher SVP, Finance and Accounting Mar 19 '24 Sale 2.09 2,971 6,196 85,686 Mar 21 04:38 PM BELVIN MARCIA SVP, Chief Scientific Officer Mar 19 '24 Sale 2.09 12,795 26,684 168,579 Mar 21 04:37 PM Landau Jeffrey B Chief Business Officer Mar 19 '24 Sale 2.09 6,562 13,685 110,060 Mar 21 04:36 PM McCarthy Sean A. CEO Dec 20 '23 Sale 1.38 13,551 18,710 454,704 Dec 22 04:16 PM BELVIN MARCIA SVP, Chief Scientific Officer Dec 20 '23 Sale 1.38 4,077 5,628 155,124 Dec 22 04:14 PM Landau Jeffrey B Chief Business Officer Dec 20 '23 Sale 1.38 4,077 5,628 86,622 Dec 22 04:12 PM ROWLAND LLOYD A General Counsel Dec 20 '23 Sale 1.38 4,077 5,629 97,996 Dec 22 04:11 PM Ogden Christopher SVP, Finance and Accounting Dec 20 '23 Sale 1.38 1,990 2,747 48,657 Dec 22 04:10 PM Ogden Christopher SVP, Finance and Accounting Dec 17 '23 Option Exercise 0.00 6,875 0 50,647 Dec 19 07:58 PM McCarthy Sean A. CEO Dec 17 '23 Option Exercise 0.00 37,500 0 468,255 Dec 19 07:57 PM Landau Jeffrey B Chief Business Officer Dec 17 '23 Option Exercise 0.00 11,250 0 90,699 Dec 19 07:56 PM ROWLAND LLOYD A General Counsel Dec 17 '23 Option Exercise 0.00 11,250 0 102,073 Dec 19 07:55 PM BELVIN MARCIA SVP, Chief Scientific Officer Dec 17 '23 Option Exercise 0.00 11,250 0 159,201 Dec 19 07:54 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite